EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024 - New Report Available

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. The course of MS seems to be unpredictable as some people diagnosed with the condition appear to be normal and healthy for a few years after diagnosis, while others may be debilitated very quickly after diagnosis. People with MS experience a host of symptoms, which may vary with the course of the disease. The estimated prevalence and incidence of MS vary greatly between countries, within countries, and by age and sex.

Full Report Details at
- http://www.fastmr.com/prod/1108087_epicast_report_multiple.aspx?afid=301

In 2014, there were a total of 909,398 diagnosed prevalent cases of MS in the 10MM, and GlobalData epidemiologists forecast that by 2024, the number of diagnosed prevalent cases of MS will grow to 942,567 cases. In 2014, there were a total of 60,535 diagnosed incident cases of MS in the 10MM, and GlobalData epidemiologists forecast the number of diagnosed incident cases of MS to grow to 62,635 cases in the 10MM in 2024.

GlobalData epidemiologists forecast the diagnosed prevalent and diagnosed incident cases of MS in the 10MM from 2014-2024 using country-specific studies published in peer-reviewed journals that provided the age- and sex-specific diagnosed prevalence and diagnosed incidence of MS in the respective markets. The epidemiologists made sure that all the selected nationally-representative studies in the respective countries assessed the prevalence and incidence using the same study definition, thereby ensuring that the results forecast for each country are comparable. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Scope

* The Multiple Sclerosis (MS) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for MS in the ten major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Canada, China, and India). It includes a 10-year epidemiological forecast of the diagnosed prevalent and diagnosed incident cases of MS segmented by sex and age in these markets. This report also includes a discussion of three types of MS; relapse remitting (RRMS), primary progressive (PPMS), and secondary progressive (SPMS).
* The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
* The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to Get this Report

* Develop business strategies by understanding the trends shaping and driving the global MS market.
* Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for MS therapeutics in each of the markets covered.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
- EpiCast Report: Hodgkin's Lymphoma - Epidemiology Forecast to 2024
- EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2024
- EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023
- EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024